ERIN PEARSON: Open Payments
NPI 1629658232 · BOSTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,623 in 56 payments from 28 companies in 2025. Trend: 2023 $313 · 2024 $2,224 · 2025 $1,623
Food & beverage: $1,623
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 7 | $195 |
| Celgene Corporation | 5 | $127 |
| Astellas Pharma US Inc | 1 | $126 |
| Syndax Pharmaceuticals, Inc. | 1 | $122 |
| AstraZeneca Pharmaceuticals LP | 3 | $88 |
| Genmab U.S., Inc. | 3 | $83 |
| GENZYME CORPORATION | 3 | $68 |
| Secura Bio, Inc. | 3 | $66 |
| Daiichi Sankyo Inc. | 3 | $65 |
| Legend Biotech USA Inc. | 1 | $63 |
Products named: SCEMBLIX, Vyloy, REVUFORJ, Epkinly, REBLOZYL, CALQUENCE, COPIKTRA, Vanflyta.
Industry payments across MA — which companies pay providers there.
